Table 3.
Number of interventions over 12 months in acute central retinal vein occlusion
| Outcome | Baseline ischemia status by SD-OCT grading
|
P-value | ||
|---|---|---|---|---|
| 1 (mild) | 2 (moderate) | 3 (severe) | ||
| Number of anti-VEGF injections | 6 (5, 9), 11 | 6 (4, 9), 12 | 6 (3, 7), 12 | 0.8540 |
| Number of PRPs | 0 (0, 0), 0 | 0 (0, 0), 1 | 0 (0, 0), 1 | 0.5094 |
| Number of grid laser treatments | 0 (0, 0), 1 | 0 (0, 0), 0 | 0 (0, 0), 0 | 0.3679 |
| Number of intravitreal steroid injections | 0 (0, 0), 1 | 0 (0, 0), 1 | 0 (0, 0), 2 | 0.9238 |
| Incisional glaucoma procedures (total cases: number of cases of specified ischemia grade) | 1:13 | 1:17 | 0:9 | 0.5712 |
| Laser cyclophotocoagulation (total cases: number of cases of specified ischemia grade) | 1:13 | 0:17 | 1:9 | 0.2941 |
Notes: The number of anti-VEGF injections applied for 12 months following the diagnosis of central retinal vein occlusion. Entries are medians followed by interquartile ranges in parentheses, in turn, followed by the maximum number for the subgroup. The number of anti-VEGF injections is the sum of bevacizumab, ranibizumab, and aflibercept injections. The number of intravitreal steroid injections is the sum of intravitreal triamcinolone and dexamethasone sustained release device injections.
Abbreviations: PRPs, panretinal photocoagulations; SD-OCT, spectral domain optical coherence tomography; VEGF, vascular endothelial growth factor.